Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen

Nasrin Amirrajab 1 , 2 , Hamid Badali 3 , Mojtaba Didehdar 4 , Mohammad Hosein Afsarian 5 , Rasoul Mohammadi 6 , Nazanin Lotfi 3 and Tahereh Shokohi 3 , *
Authors Information
1 Department of Laboratory Sciences, School of Paramedicine and Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
3 Department of Medical Mycology and Parasitology, Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
4 Department of Medical Mycology and Parasitology, Faculty of Medicine, Arak University of Medical Sciences, Arak, IR Iran
5 Department of Microbiology, Fasa University of Medical Sciences, Fasa, IR Iran
6 Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Jundishapur Journal of Microbiology: May 01, 2016, 9 (5); e36638
  • Published Online: April 23, 2016
  • Article Type: Research Article
  • Received: January 29, 2016
  • Revised: March 11, 2016
  • Accepted: March 26, 2016
  • DOI: 10.5812/jjm.36638

To Cite: Amirrajab N, Badali H, Didehdar M, Afsarian M H, Mohammadi R, et al. In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen, Jundishapur J Microbiol. 2016 ; 9(5):e36638. doi: 10.5812/jjm.36638.

Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Pfaller MA. The epidemiology of invasive candidiasis. 2012;
  • 2. Yazdanparast SA, Khodavaisy S, Fakhim H, Shokohi T, Haghani T, Nabili M, et al. Molecular characterization of highly susceptible Candida africana from Vulvovaginal Candidiasis Mycopathologia 2015; 180(5-6): 137-23[DOI][PubMed]
  • 3. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012; 36(2): 288-305[DOI][PubMed]
  • 4. Glockner A, Cornely OA. Candida glabrata--unique features and challenges in the clinical management of invasive infections. Mycoses. 2015; 58(8): 445-50[DOI][PubMed]
  • 5. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol. 2012; 50(11): 3435-42[DOI][PubMed]
  • 6. Lotfi N, Shokohi T, Nouranibaladezaei SZ, Nasrollahi Omran A, Kondori N. High recovery rate of non-albicans Candida species isolated from burn patients with candidemia in Iran Jundishapour J Microbiol. 2015; 8(10)[DOI]
  • 7. Fesharaki SH, Haghani I, Mousavi B, Kargar ML, Boroumand M, Anvari MS, et al. Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser J Med Microbio 2013; 62: 1763-7[DOI][PubMed]
  • 8. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis. 2004; 48(3): 201-5[DOI][PubMed]
  • 9. Ben-Ami R, Hilerowicz Y, Novikov A, Giladi M. The impact of new epidemiological cutoff values on Candida glabrata resistance rates and concordance between testing methods. Diagn Microbiol Infect Dis. 2014; 79(2): 209-13[DOI][PubMed]
  • 10. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012; 50(4): 1199-203[DOI][PubMed]
  • 11. Tscherner M, Schwarzmüller T, Kuchler K. Pathogenesis and antifungal drug resistance of the human fungal pathogen Candida glabrata. Pharmaceuticals. 2011; 4(1): 169-86[DOI]
  • 12. Lyon GM, Karatela S, Sunay S, Adiri Y, Candida Surveillance Study I. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010; 48(4): 1270-5[DOI][PubMed]
  • 13. Prasad R, Kapoor K. Multidrug Resistance in Yeast Candida. Int Rev Cytol. 2005; 242: 215-48[DOI]
  • 14. Afsarian MH, Badali H, Boekhout T, Shokohi T, Katiraee F. Multilocus sequence typing of Candida albicans isolates from Burn Intensive Care Unit (BICU) in Iran J Med Microbiol 2015; 64: 248-53[PubMed]
  • 15. Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd informational supplement. 2008;
  • 16. Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement. 2012;
  • 17. Xiao M, Fan X, Chen SC, Wang H, Sun ZY, Liao K, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015; 70(3): 802-10[DOI][PubMed]
  • 18. Razzaghi-Abyaneh M, Sadeghi G, Zeinali E, Alirezaee M, Shams-Ghahfarokhi M, Amani A, et al. Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. J Mycol Med. 2014; 24(2)-50[DOI][PubMed]
  • 19. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012; 18 Suppl 7: 19-37[DOI][PubMed]
  • 20. Ramsay S, Astill N, Shankland G, Winter A. Practical management of recurrent vulvovaginal candidiasis. Trends Urol Gynaecol Sex Health. 2009; 14(6): 18-22[DOI]
  • 21. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001; 39(9): 3254-9[PubMed]
  • 22. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ, Sentry Participants Group . Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol. 2002; 40(3): 852-6[PubMed]
  • 23. Taj-Aldeen SJ, Kolecka A, Boesten R, Alolaqi A, Almaslamani M, Chandra P, et al. Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection. 2014; 42(2): 393-404[DOI][PubMed]
  • 24. Shokohi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol. 2011; 4-26
  • 25. Badiee P, Alborzi A, Shakiba E, Farshad S, Japoni A. Susceptibility of Candida species isolated from immunocompromised patients to antifungal agents. East Mediterr Health J. 2011; 17(5): 425-30[PubMed]
  • 26. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med. 2010; 13(4): 282-7[PubMed]
  • 27. Zomorodian K, Rahimi MJ, Pakshir K, Motamedi M, Ghiasi MR, Rezashah H. Determination of antifungal susceptibility patterns among the clinical isolates of Candida species. J Glob Infect Dis. 2011; 3(4): 357-60[DOI][PubMed]
  • 28. Katiraee F, Khosravi AR, Khalaj V, Hajiabdolbaghi M, Khaksar AA, Rasoulinejad M. In vitro antifungal susceptibility of oral candida species from Iranian HIV infected patients. Tehran Univ Med Sci. 2012; 70(2)
  • 29. Fidel PJ, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999; 12(1): 80-96[PubMed]
  • 30. Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol. 2009; 47(10): 3185-90[DOI][PubMed]
  • 31. Pfaller MA, Diekema DJ, International Fungal Surveillance Participant G. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect. 2004; 10 Suppl 1: 11-23[PubMed]
  • 32. Ruan SY, Chu CC, Hsueh PR. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. Antimicrob Agents Chemother. 2008; 52(8): 2919-22[DOI][PubMed]
  • 33. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis. 2006; 42(7): 938-44[DOI][PubMed]
  • 34. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother. 2010; 54(12): 5042-7[DOI][PubMed]
  • 35. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation. 2005; 80(6): 868-71[PubMed]
  • 36. Spellberg BJ, Filler SG, Edwards JJ. Current treatment strategies for disseminated candidiasis. Clin Infect Dis. 2006; 42(2): 244-51[DOI][PubMed]
  • 37. Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother. 2005; 49(9): 3616-23[DOI][PubMed]
  • 38. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013; 51(8): 2571-81[DOI][PubMed]
  • 39. Mortezaee VKP, Mahmoudi M, Safara M, Shekari H. In vitro Susceptibilities of Iranian Clinical nonalbicans Candida species to Caspofungin and Ketoconazole. J Basic Appl Sci Res. 2012; 2: 1608-14
  • 40. Pappas PG, Kauffman CA, Andes D, Benjamin DJ, Calandra TF, Edwards JJ, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(5): 503-35[DOI][PubMed]
  • 41. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol. 2006; 44(5): 1740-3[DOI][PubMed]
  • 42. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011; 14(3): 164-76[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments